A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Clinical trial NCT02637531 · UNKNOWN

Trial details

NCT number: NCT02637531
Sponsor: Infinity Pharmaceuticals, Inc.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumors (Part A/B/C/D)Non-small Cell Lung Cancer (Part E)Melanoma (Part E)Squamous Cell Cancer of the Head and Neck (Part E)Triple Negative Breast Cancer (Part F)Adrenocortical Carcinoma (Part G)Mesothelioma (Part G)High-circulating Myeloid-derived Suppressor Cells (Part H)

Start date: 2015-12-01
Primary completion: 2022-01-01
Enrollment: 219

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.